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Abstract 
Prostaglandin G/H synthase (PGHS) is a key enzyme in cellular prostaglandin (PG) synthesis and is the target of non-steroidal anti-inflammatory 
agents. PGHS occurs in two isoforms, termed PGHS-1 and PGHS-2. These isoforms differ in several respects, including their enzymatic activity 
following acetylation by aspirin. While PG synthesis by both isofonns is inhibited by aspirin, 15R-hydroxyeicosatetraenoic a id (15-R-HETE) 
synthesis by PGHS-2, but not PGHS-1, is stimulated by preincubation with aspirin. We have mutated the putative aspirin acetylation site of hPGHS-2, 
and expressed the mutants in COS-7 cells using recombinant vaccinia virus. Enzyme activity and inhibitor sensitivity studies provide evidence that 
Sersi6 is the aspirin acetylation site of human PGHS-2 and that substitution of a methionine residue at this position can mimic the effects of aspirin 
acetylation on enzyme activity. 
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1. Introduction 
The first two commited steps in the cellular synthesis 
of all prostaglandins (PGs), namely the oxygenation of 
arachidonic acid to prostaglandin G, (PGGJ and the 
reduction of PGG, to prostaglandin H, (PGH,) are cat- 
alyzed by the enzyme prostaglandin G/H synthase 
(PGHS) [l]. PGHS also represents the target of various 
non-steroidal anti-inflammatory drugs (NSAIDS), in- 
cluding aspirin and indomethacin [2,3]. 
A constitutively expressed form of PGHS, termed 
PGHS- 1, has been detected in a variety of cell types from 
different species [4-61. A second isoform (PGHS-2) is 
rapidly induced in response to growth factors, cytokines 
and endotoxin [3,7-l 1). This has lead to the suggestion 
that PGHS-1 may be responsible for PG synthesis under 
normal physiological conditions, with PGHS-2 being 
primarily responsible for PG synthesis during inflamma- 
tory responses [3,12,13]. PGHS-2 may therefore repre- 
sent a novel target for NSAIDS. This has resulted in 
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considerable interest in biochemical and pharmacologi- 
cal comparisons of PGHS-1 and PGHS-2 [12-141. 
In addition to the synthesis of PGs following incuba- 
tion with arachidonic acid, PGHS-1 and PGHS-2 both 
synthesize low levels of 15-HETE and 1 l-HETE [ 14-171. 
Acetylation of PGHS-1 by aspirin results in an inhibition 
of PG synthesis, but does not alter 15HETE synthesis 
[12-141. This difference in activity suggests that the ac- 
tive sites of the two isoforms of PGHS have distinct 
structural features. The aspirin acetylation site of sheep 
PGHS-I has been identified as Ser530 [18,19], and it has 
been proposed that the aspirin acetylation sites of human 
PGHS-1 (hPGHS-1) and human PGHS-2 (hPGHS-2) 
are Ser529 [20] and Se? [7], respectively. In an attempt 
to mimic the effects of aspirin acetylation on hPGHS-2 
activity we mutated the putative aspirin acetylation site 
of the enzyme by site-directed mutagenesis and assessed 
the effects of amino acid substitutions on enzyme activity 
and the sensitivity of this activity to aspirin. 
2. Materials and methods 
2.1. Chemicals and reagents 
Nucleotides and dNTPs were obtained from Boehringer Mannheim 
(Montreal, Quebec, Canada). All other reagents were obtained from 
Pharmacia (Montreal, Quebec, Canada). ‘251-labeled protein A (10 
mCi/mg) and [a-32P]dCTP (3,000 Cilmmol) were purchased from NEN- 
DuPont (Burlington, Ontario, Canada). 
All rights reserved. 
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2.2. Cell culture 
COS-7 and 143B TK- cell lines were obtained from the American 
Type Culture Collection and grown as monolayer cultures in a humid- 
ified environment of 6% CO2 at 37°C in Dulbecco’s modified Eagle’s 
medium (Sigma, St. Louis, MO) supplemented with 10% fetal bovine 
serum, 10 mM glutamine, lOO,~g/ml streptomycin, 100 units/ml penicil- 
lin, and 100 &ml gentamicin (GibcolBRL, Burlington, Ontario, Can- 
ada), 25 mM HEPES, pH 7.4. For 143B TK- cells, 25 &ml of 5- 
bromo-2’-deoxyuridine was also added to the culture medium. 
2.3. Site-directed mutagenesis 
All general recombinant DNA techniques and site-directed mut- 
agenesis procedures were performed as described elsewhere 1211. 
Briefly, the PstI fragment of hPGHS-2 was subcloned from pTMl- 
hPGHS-2-3’fl [14] into the multiple cloning site of Bluescript (Strat- 
agene, LaJolla, CA) to yield PBS-Pst-hPGHS-2. The preparation of 
single stranded DNA from PBS-Pst-hPGHS-2 and the introduction of 
mutations into the cDNA of PGHS-2 was then performed using the 
Amersham oligonucleotide-directed mutagenesis kit (Amersham, Ar- 
lington Heights, IL) according to the manufacturer’s instructions. Sin- 
gle amino acid changes were introduced using appropriate oligonucleo- 
tides 33 nucleotides in length with 3 nucleotide mismatches. The PstI 
fragments containing the mutated sequences were then subcloned back 
into the PstI site of their plasmid of origin to yield the constructs 
pTMl-hPGHS-2(Se?-Met) and pTMl-hPGHS-2(Sersi6-Gln). The 
mutant proteins derived from these constructs are hPGHS-2(Ser5’6- 
Met) and hPGHS-2(Se?-Gln), where the serine at residue 516 of 
hPGHS-2 is mutated to a methionine or glutamine residue, respectively. 
Oligonucleotides were synthesized using the 380B DNA synthesizer 
(Applied Biosystems, Mississauga, Ont., Canada). Introduction of the 
desired mutation was confirmed by dideoxy sequencing, using a T7 
sequencing kit (Pharmacia). 
2.4. Construction of recombinant vaccinia virus transfer vectors 
The recombinant vaccinia virus used for the expression of human 
prostaglandin G/H synthase-2 (termed W:hPGHS-2-3’fl) has previ- 
ously been described [14]. All procedures for the generation of recombi- 
nant vaccinia viruses, infection of COS-7 cells with these viruses in the 
presence of the helper virus W:TF7-3, and the preparation of micro- 
somal protein fractions from infected cells have been described else- 
where [14]. 
2.5. Prostaglandin GIH synthase assays 
Assays for the synthesis of PGE, and 15-HETE by microsome prep- 
arations from COS-7 cells have been described elsewhere [14]. Briefly 
each assay contained 5&125 pg of protein in a total volume of 200 ,~l 
containing 100 mM Tris-HCl, pH 7.4, and 10 mM EDTA. Samples 
were thenincubated at room temperature for 30 min in the presence 
of asnirin (100 uM) or ethanol vehicle (2 ~1). followed bv incubation 
for 5.min in the’presence of indomethacin (1 il) or dimethyl sulphoxide 
vehicle. Reduced glutathione (2 pl), phenol (2 ~1) and hematin (1 ,~l) 
were then added to final concentrations of 1 mM, 0.5 mM and 0.5 PM, 
respectively. Reactions were initiated by the addition of arachidonic 
acid (2~1; final concentration 20pM) followed by incubation for 30 min 
at room temperature. Reaction products were immediately extracted 
into chloroform and analyzed by reverse-phase HPLC using a solvent 
system of 75% methanol/O.Ol% acetic acid as previously described [14]. 
The identity of reaction products was verified by coinjection with au- 
thentic standards and mass spectrometry, and the amounts of reaction 
products were determined using a standard curve of authentic 
standards. Aliquots from these assays were also analyzed for PGE, 
concentrations using a radioimmunoassay (NEN-DuPont) as previ- 
ously described [14]. 
3. Results 
3.1. Expression of hPGHS-2 and hPGHS-2 mutants in 
COS- 7 cells 
By enzyme activity measurements and immunoblot 
analysis [14], PGHS expression is extremely low in mi- 
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Fig. 1. Immunoblot analysis of vaccinia virus-directed expression of 
hPGHS-2 and hPGHS-2 mutants in COS-7 cells. COS-7 cells were 
infected with the indicated viruses, cultured for 26 h, harvested and then 
used for the preparation of microsomes. Microsomal proteins were 
subjected to SDS-PAGE on precast 10% Tris-glycine acrylamide gels 
(Novex, San Diego, CA) and electrophoretically transferred to nitrocel- 
lulose membranes. Immunoblot analysis was then performed using an 
anti-PGHS-2 antipeptide antiserum (Cayman, Ann Arbor, MI) and 
[‘*‘I]protein A as previously described [21]. Expression of hPGHS-2 was 
assessed in microsomes prepared from cells co-infected with recombi- 
nant vaccinia virus for hPGHS-2 (lanes l-3), hPGHS-2(Ser516-Met) 
(lanes 46) or hPGHS-2(Ser5i6-Gln) (lanes 7-9) and helper virus. The 
amount of protein loaded per lane was 1 pg (lanes 1, 4 and 7) 5 fig 
(lanes 2, 5 and 8) or 10 pg (lanes 3, 6 and 9). Blots were exposed to 
Kodak XAR-2 film at -80°C for 3 h. The migration positions of 
molecular weight markers are indicated. 
crosomes from wild-type COS-7 cells. Immunoblot anal- 
ysis (Fig. 1) demonstrates a high level expression of 
hPGHS-2, hPGHS-2(Ser5i6-Met) or hPGHS-2(Ser516- 
Gln) in 100,000 x g membrane preparations of COS-7 
cells following infection with the appropriate recombi- 
Table 1 
Prostaglandin and 15-HETE synthesis by hPGHS-2 and hPGHS- 
2(Ser516-Met) 
Prostaglandin E, (ng) 15-HETE (ng) 
-ASA +ASA -ASA +ASA 
T7 control 0.06 0.06 
hPGHS-2 786 192 
hPGHS-2(Ser5’6-Met) 9 10 
nd nd 
13 154 
266 261 
Microsome preparations from mock-infected COS-7 cells (T7 control) 
or COS-7 cells expressing hPGHS-2 or hPGHS-2(Ser5’6-Met) were as- 
sayed in duplicate for enzyme activity as described in section 2. Results 
are shown as ng of product per assay, with the amount of protein for 
each assay being adjusted to give equivalent amounts of hPGHS-2 or 
mutant protein as determined by densitometric scanning of im- 
munoblots (Fig. 1). Less than 10% variability was observed between 
duplicate samples. The amounts of protein per assay were 100 pg, 50 
pg, and 125 pg for T7 control, hPGHS-2, and hPGHS-2(SerSu’-Met), 
respectively. nd = not detectable (< 1 ng). 
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Fig. 3. Chiral phase HPLC analysis of 15-HETE synthesised by hPGHS-Z(Ser ‘16-Met). The following samples were analyzed on a chiral phase column 
as previously described [14]. (A) A mixture containing 100 ng of each of the methyl esters of 15-S-HETE and 15-R-HETE. (B) 100 ng of the methyl 
ester of 15-HETE synthesized by microsomes from COS-7 cells containing hPGHS-Z(Ser 5’6-Met). (C) Co-injection of 50 ng of the methyl esters of 
15-S-HETE. 15-R-HETE and 15-HETE derived from hPGHS-2(Ser5’6-Met). In B and C the retention times of 15-S-HETE and 15-R-HETE are 
indicated. 
4. Discussion 
In the present study, site-directed mutagenesis was 
used to mutate Ser5’6 of hPGHS-2, which is the putative 
aspirin acetylation site of the enzyme. Replacement of 
this residue with a methionine residue decreased PG syn- 
thesis by the enzyme dramatically, with the remaining 
activity being insensitive to treatment of the enzyme with 
aspirin. This is consistent with Ser516 being the aspirin 
acetylation site of hPGHS-2 and, similar to sheep PGHS- 
1 [18] and human PGHS-1 [20], that the serine residue 
at this site is not absolutely required for enzyme activity. 
These results also suggest hat there is no other aspirin 
acetylation site in hPGHS-2 which affects PG produc- 
tion. 
We have demonstrated that hPGHS-2(Se?-Met) can 
synthesize similar levels of 15-R-HETE from ara- 
chidonate to that observed following aspirin acetylation 
of hPGHS-2. This suggests that the side chain of 
methionine may sterically mimic an acetylated serine at 
the active site of hPGHS-2, and may provide a useful 
model system to study the effect of aspirin acetylation on 
the structure and activity of hPGHS-2. The demonstra- 
tion that indomethacin can inhibit 15-HETE synthesis 
by hPGHS-2(Ser516-Met) and aspirin-acetylated 
hPGHS-2 demonstrates that NSAIDS can still be acco- 
modated at the active site of PGHS-2 following modifi- 
cation of Ser516. When Ser516 was replaced with a glutam- 
ine residue, the resulting mutant could synthesize only 
extremely low levels of PGs and no detectable 15-HETE. 
This suggests that the side chain of glutamine, which is 
more polar and conformationally constrained than that 
of a methionine residue, prevents the productive binding 
of arachidonate to the enzyme. 
The high level synthesis of 15-R-HETE by aspirin- 
acetylated hPGHS-2, which is mimicked by hPGHS- 
2(Ser516-Met), is a feature which clearly distinguishes 
PGHS-2 from PGHS-1. A comparison of the structural 
features of PGHS-2 to those recently reported for 
PGHS-1 [22] may provide a greater understanding of the 
basis for this difference. 
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